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Summary
Telomerase has been proposed as a selective target
for cancer chemotherapy. We established a forward
chemical genetics approach using a yeast strain with
shortened telomere length. Since this strain rapidly
enters cell senescence in the absence of active telo-
merase, compounds that induce selective growth
defects against telomere-shortened yeast could be
candidates for drugs acting on telomeres and telome-
rase. We screened our microbial products library and
identified three structurally unrelated antibiotics,
chrolactomycin, UCS1025A, and radicicol, as active
compounds. Detailed analysis showed that chrolacto-
mycin inhibited human telomerase in a cell-free assay
as well as in a cellular assay. Long-term culture of can-
cer cells with chrolactomycin revealed population-
doubling-dependent antiproliferative activity accom-
panied by telomere shortening. These results suggest
that chrolactomycin is a telomerase inhibitor, and that
the yeast-based assay is useful for discovering the
small molecules acting on human telomerase.
Introduction
Telomeres are nucleoprotein structures highly con-
served in organisms ranging from yeasts to mammals
and are essential for preventing aberrant recombination
and protecting against exonucleolytic DNA degradation
[1]. Telomerase is a ribonucleoprotein enzyme complex
that maintains the telomeric structures at the chromo-
somal termini by adding the G-rich strand of telomere
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ogy, 1266 Tamura, Nagahama, Shiga, 526-0829, Japan.repeats [2]. Normal human cells either do not express
telomerase or express very low levels of it, and, thus,
telomeres progressively shorten with each cell division
due to incomplete replication of lagging strand DNA
synthesis. Loss of telomeres to below a threshold value
is believed to induce senescence. In cancer cells, how-
ever, telomere length is stably maintained by telome-
rase, generally at relatively short lengths compared to
those in normal somatic cells [3–5]. Thus, telomerase
activation is assumed to be the main pathway by which
cancer cells become immortal. These properties predict
a substantial therapeutic window between cancer and
normal cells, and they make telomerase a potentially
universal and relatively safe anticancer target for drug
discovery.
A number of small-molecule telomerase inhibitors
have been reported [6, 7]. Most were identified by
random biochemical screening to measure human telo-
merase inhibitory activity in cell-free systems or by de-
sign of modified oligonucleotides, like GRN163 and
GRN163L, that target the 11 nucleotide template region
of human telomerase RNA (TR) [8, 9]. In some cases, pro-
longed inhibition of telomerase in various tumor cell lines
results in cellular senescence or apoptosis accompa-
nied by telomere shortening.
To identify telomerase inhibitors, we tried a different
screening strategy by using a yeast-based cellular as-
say. We had successfully discovered lead compounds
for anticancer therapy by using forward chemical genet-
ics approaches, including Ras farnesyltransferase inhib-
itors [10], Hsp90 antagonists [11, 12], Src signal trans-
duction inhibitors [13], and proteasome inhibitors [14].
We therefore attempted to develop a new assay system
for telomerase inhibitors by applying yeast genetics to
drug screening.
We report here the discovery of structurally diversi-
fied and unrelated antibiotics, chrolactomycin [15],
UCS1025A [16], and radicicol [17], as a new class of tel-
omerase inhibitors identified by a yeast-based assay.
Detailed analysis of chrolactomycin showed that this
compound inhibited human telomerase in a cell-free as-
say as well as in a cellular assay. Long-term culture with
chrolactomycin revealed population-doubling (PD)-
dependent antiproliferative activity accompanied by
telomere shortening against human tumor cells. These
results suggest that chrolactomycin is an attractive can-
didate for telomerase inhibition and that the yeast-based
assay is useful for the discovery of small molecules act-
ing on human telomerase.
Results
Screening for Telomerase Inhibitors
with a Yeast-Based Assay
In budding yeast, mutation of EST1 (ever shorter telo-
mere 1), a component of telomerase, leads to progres-
sive telomere shortening and a gradual decrease in
growth rate [18]. We produced KY19614 strain, an
EST1 null mutant S. cerevisiae harboring the plasmid
carrying an EST1 gene whose expression was under
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184the control of a galactose-inducible and glucose-repres-
sive GAL1 promoter. This strain (KY19614) was inocu-
lated into glucose- or galactose-containing medium
and grown for 13 days by diluting the cultures with fresh
medium every 24 hr. Southern blot analysis to measure
the terminal restriction fragment (TRF) length revealed
that this strain exhibited a progressive telomere short-
ening in glucose medium, indicating a lack of active tel-
omerase in the absence of EST1 expression (Figure 1).
We established a forward chemical genetics ap-
proach by using this budding yeast strain with short-
ened telomere length, which was produced by condi-
tional deficiency of the EST1 gene (Figure 2A). The
growth of the yeast with critically shortened telomere
length depended on the active telomerase regulated
by the expression of EST1, since this strain could grow
in galactose medium, but not in glucose medium. Under
conditions in which this strain rapidly entered cell senes-
cence and exhibited a growth-defective phenotype in
the absence of active telomerase, compounds that in-
duce selective growth defects in this telomere-short-
ened yeast strain cultured in galactose medium repre-
sent new drug candidates acting on telomeres and
telomerase. A parallel screen was conducted by using
the telomere-elongated yeast strain to distinguish small
molecules that were simply cytotoxic from those acting
on telomeres and telomerase.
We selected one of our natural product libraries as
a source of screening compounds. Approximately 600
microbial metabolites were screened for their selective
activity against telomere-shortened yeast in the paper
disc assay. As shown in Figure 2B, 5-fluorouracil (pyrim-
idine antagonist), nystatin (cell membrane sterol binder),
ketoconazole (ergosterol synthesis inhibitor), and wort-
mannin (phosphatidylinositol 3-kinase inhibitor) were
representative nonselective inhibitors detected in this
assay, and they yielded inhibition of growth of the two
yeast strains equally. Glucose, as a positive control, re-
pressed the EST1 gene expression and inhibited the
growth of the telomere-shortened yeast strain specifi-
cally. Although most compounds with anti-yeast activity
exhibited nonselective activity against both yeast
strains, only three compounds, chrolactomycin,
UCS1025A, and radicicol, exhibited selective inhibitory
activity against the telomere-shortened yeast strain.
Through screening and the detection of reproducible
activities, we concluded that these three structurally un-
related antibiotics were active compounds in this yeast-
based assay (Figure 2C).
To confirm the principle of the yeast-based assay
directing the identification of the compound to regulate
telomere length, we investigated the effect on telomere
length of yeast treated with one of the active com-
pounds, radicicol. NBW6 strain, a wild-type S. cerevi-
siae, was inoculated into 0, 2, 10, or 50 mM radicicol-con-
taining liquid medium and grown for 27 days by diluting
the cultures with fresh radicicol-containing medium
every 24 hr. Southern blot analysis to measure TRF
length revealed time- and concentration-dependent
telomere shortening (Figure S1; see the Supplemental
Data available with this article online). This result sug-
gested that the active compounds screened in this as-
say could actually induce telomere shortening, presum-
ably due to inhibition of telomerase function in yeast.Inhibition of Human Telomerase by Screening
Hit Compounds in a Cell-free Assay
We were interested in whether the active compounds ex-
hibited inhibitory activity against human telomerase be-
cause we would like to assess the potentialities of the ac-
tive compounds as antitumor agents targeting human
telomerase. To examine the effects of screening hit com-
pounds on the activity of human telomerase in a cell-free
assay, we performed the telomere repeat amplification
protocol (TRAP) assay [3] by using crude cellular ex-
tracts from A431 human tumor cells as a source of telo-
merase. Chrolactomycin exhibited potent inhibition of
human telomerase in a dose-dependent manner with
an IC50 of 0.5 mM (Figure 3A). UCS1025A also exhibited
potent inhibition of human telomerase with an IC50 of
1.3 mM, but radicicol did not exhibit direct inhibition of
human telomerase in TRAP assay (data not shown).
These results demonstrated that the selective inhibition
by chrolactomycin or UCS1025A of growth of the telo-
mere-shortened yeast strain was due to direct inhibition
of telomerase activity in yeast. In this report, we focus on
the study of the effects of chrolactomycin on human tel-
omerase. Details of the mechanism of action of
UCS1025A and radicicol will be reported elsewhere.
Telomerase Inhibition in Human Cancer Cells
by Chrolactomycin
We next examined whether chrolactomycin was capable
of inhibiting telomerase activity in human tumor cells. To
examine the long-term effects of chrolactomycin on tel-
omerase-positive human renal carcinoma ACHN cells,
we first determined the drug concentration at which cellu-
lar telomerase could be inhibited without acute growth-
inhibitory effects. Chrolactomycin had only minor effect
on short-term cell viability and proliferation, as deter-
mined in a 4 day cytotoxicity assay with concentrations
Figure 1. Effect of EST1 Gene Expression on Telomere Length
The S. cerevisiae KY19614 (DEST1 GAL1-EST1) strain was grown
on galactose- or glucose-containing media and was subcultured
every 24 hr. Genomic DNA was extracted, digested with XhoI,
and fractionated by agarose gel electrophoresis. After Southern
blotting, telomeric DNA was detected with poly(d[CA/GT]) probe.
The bracket indicates the telomeric GT repeat band derived from
Y0 element-containing chromosomes. Cells were estimated to
have undergone between five and seven divisions per passage in
liquid medium. The numbering at the top of the lanes (13, 43,
etc.) indicates the number of times of passage in liquid culture.
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185Figure 2. Selective Growth Defects in Telo-
mere-Shortened Yeast by Chrolactomycin,
UCS1025A, and Radicicol
(A) The principle of the yeast-based assay to
identify telomerase inhibitors.
(B) Sterile filter disks (diameter is 8 mm) im-
pregnated with 15 nmol chrolactomycin
(telomerase inhibitor), 30 nmol UCS1025A
(telomerase inhibitor), 50 nmol radicicol (telo-
merase inhibitor/Hsp90 antagonist), 10 nmol
5-fluorouracil (pyrimidine antagonist), 20
nmol nystatin (cell membrane sterol binder),
20 nmol ketoconazole (ergosterol synthesis
inhibitor), 200 nmol wortmannin (phosphati-
dylinositol 3-kinase inhibitor), or 22 mmol glu-
cose (positive control to shut offEST1expres-
sion) were placed on two agar plates,
containing telomere-shortened or -elongated
yeast strains, simultaneously. The diameters
of the growth-inhibitory zone surrounding
the paper disk were measured after 2 days
of incubation at 30ºC. Representative results
of three similar experiments are shown.
(C) Chemical structures of chrolactomycin,
UCS1025A, and radicicol.of 1 or 2 mM, the same level as the IC50 value for inhibition
of telomerase in a cell-free assay. ACHN cells were cul-
tured with chrolactomycin at 1 or 2 mM for 7 days. At
this time point, telomerase activity in cell extract was re-
duced by 76% at 1 mM and by 85% at 2 mM (Figures 3B
and 3C). Similar results were obtained with other human
cancer cells, such as renal carcinoma Caki-1 and colo-
rectal adenocarcinoma WiDr, treated with chrolactomy-
cin (data not shown). On the basis of these observations,
the concentration of chrolactomycin for use in long-term
culture was determined to be 1 or 2 mM.
Effects on Telomere Length and Cell Growth
of Human Cancer Cells after Long-Term Treatment
with Chrolactomycin
During long-term culture, ACHN cells were monitored
periodically by telomere length estimation by using
Southern blot analysis (Figure 4A). Control cells treated
with DMSO alone exhibited a heterogeneous size distri-
bution, with an average telomere length of w2.3 kb
(Figure 4B). TRF length was progressively shortened
as cells were propagated in the presence of chrolacto-mycin. The telomere erosion rates between day 7 and
day 39 were calculated to be 17 and 40 bp/PD at 1 and
2 mM, respectively (Figure 4D). In contrast, DMSO-
treated cells maintained a stable TRF length. These telo-
mere erosion rates are slightly lower than the speed of
telomere erosion reported in the absence of telomerase
(25–200 bp/PD), which is largely due to the end replica-
tion problem [19–21].
We characterized the growth properties of chrolacto-
mycin-treated cells (Figure 4C). ACHN cells in the ab-
sence or presence of 1 or 2 mM chrolactomycin initially
exhibited only minor differences in proliferation. After
60 days, however, 2 mM chrolactomycin-treated ACHN
cells exhibited nearly complete inhibition of prolifera-
tion. One mM chrolactomycin-treated cells exhibited a
delay of proliferation.
Cell Cycle Distribution and Senescence-Associated
b-Galactosidase Staining in Human Cancer Cells
Treated with Chrolactomycin
Analysis of cell cycle distribution of chrolactomycin-
treated ACHN cells for 46 days was performed by
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186Figure 3. Inhibition of Human Telomerase by
Chrolactomycin in a Cell-free Assay and in
a Cellular Assay
(A) Chrolactomycin was incubated with the
extracts from human epidermoid carcinoma
A431 cells for 30 min. An aliquot of the mix-
ture was subjected to TRAP analysis by us-
ing the TRAPEZE XL telomerase detection
kit for measurement of telomerase activity.
Values are the means (n = 2).
(B) Human renal carcinoma ACHN cells were
preincubated for 24 hr at 37ºC and were then
treated with chrolactomycin at 1 or 2 mM for
7 days. After washing with PBS, cell lysate
was prepared with lysis buffer. Extracts
with equivalent protein concentrations were
prepared and subjected to TRAP analysis
with the TRAPEZE telomerase detection kit
for measurement of telomerase activity.
(C) Percentages of inhibition of telomerase in
ACHN cells by chrolactomycin at 1 and 2 mM
were 76% and 85%, respectively, as deter-
mined by scanning the gel described in
Figure 3B. Values are the means6 SD (n = 3).propidium iodide signal staining with flow cytometry
(Figure 5A). Chrolactomycin at 1 mM increased the pop-
ulation of cells in G2/M phase and decreased that in G1
phase. Chrolactomycin at 2 mM increased the population
of cells in the G2/M phase, the population of cells in the
aneuploidy fraction, and the population of cells in the
sub-G1 fraction.
Chrolactomycin-treated, late-passage ACHN cells ex-
hibited distinctive morphological features associated
with cellular senescence. In contrast to DMSO-treated
cells, ACHN cells treated with 2 mM chrolactomycin at
day 50 exhibited a flattened morphology and increased
size, contained multiple nuclei, and exhibited induction
of senescence-associated b-galactosidase activity
(Figure 5B). These results, in conjunction with those for
cell cycle analysis, indicate that chrolactomycin induced
cellular senescence in human tumor cells as a major ef-
fect of long-term treatment, consistent with previously
reported cellular effects of telomerase inhibition [22–24].
Discussion
Yeast-Based Screening Focused on Replicative
Senescence Is Useful for Identifying Direct
or Indirect Inhibitors of Human Telomerase
The focus of our research has been to identify novel
telomerase inhibitors. A number of small-molecule telo-
merase inhibitors have been reported. Most inhibitors
have been identified by random biochemical screening
or by design of antisense oligonucleotides. Unlike cell-
free biochemical assays, cell-based assays have beenshown to have several advantages, such as an in-
creased efficiency in selection of cell-permeable small
molecules and an ability to identify the small molecules
with several modes of action. To accomplish our objec-
tive, we established a forward chemical genetics ap-
proach and used a strategy different from those previ-
ously applied to screening for telomerase inhibitors.
We focused on replicative senescence caused by telo-
mere erosion in the absence of telomerase due to the
end replication problem. Two sets of yeast strains that
differ only in telomere length were prepared by regulat-
ing the expression of the EST1 gene. One of the test
strains was a telomere-shortened yeast strain, like hu-
man cancer cells with short telomere length and active
telomerases, and another was a telomere-elongated
yeast strain, like human stem cells with long telomere
length and active telomerases [3–5]. Since the telo-
mere-shortened yeast strain rapidly entered cell senes-
cence and exhibited a growth-defective phenotype in
the absence of active telomerase, compounds that in-
duced selective growth defects in this telomere-short-
ened yeast strain could represent new drug candidates
acting on telomeres and telomerase.
Consistent with this expectation, screening with this
yeast-based assay allowed us to identify three struc-
turally unrelated natural products, chrolactomycin,
UCS1025A, and radicicol, as inhibitors active against
human telomerase. TRAP assay with human telomerase
revealed that chrolactomycin and UCS1025A directly
inhibited telomerase activity in in vitro enzyme assays,
while radicicol did not. At the cellular level, however, all
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187Figure 4. Effects of Chrolactomycin on Telo-
mere Length and Cell Proliferation of ACHN
Cells during Long-Term Exposure
(A) Measurement of TRF in ACHN cells
treated with chrolactomycin. Genomic DNA
isolated from ACHN cells treated with chro-
lactomycin was digested and subjected to
Southern blot analysis.
(B) Mean TRF lengths calculated from size
distributions in scanned lanes.
(C) Dose-dependent inhibition of ACHN cell
proliferation by prolonged treatment with 1
or 2 mM chrolactomycin. Results of two par-
allel experiments are shown.
(D) The rates of telomere loss between day 7
and day 39 were calculated to be 17 and 40
bp/PD with 1 and 2 mM chrolactomycin treat-
ment, respectively.three compounds exhibited inhibitory effects against tel-
omerase in human cancer cells, indicating that they can
be classified into two groups of new telomerase inhibi-
tors: direct inhibitors (chrolactomycin and UCS1025A)
and an indirect inhibitor (radicicol) (see below).
Telomerase activity has been characterized for a wide
range of organisms, and genes encoding both the RNA
and protein components of the enzyme complex have
been identified [25]. The catalytic subunit human telo-
merase reverse transcriptase (TERT) was identified as
a human homolog of p123 protein in Euplotes aedicula-
tus and of Est2p inS. cerevisiae [26]. According to recent
studies, the telomerase-associated factor Est1p in S.
cerevisiae is evolutionarily conserved in humans [27].
Based on these similarities between yeast and human
telomerase components, it could be considered appro-
priate that the active compounds found by the yeast-
based assay would exhibit an inhibition of human telo-
merase activity through effects on phylogenetically
conserved portions of telomerase components.
Radicicol was originally isolated as an antifungal anti-
biotic and has been recently rediscovered with its
unique mode of action as an Hsp90 antagonist in our
laboratories [11, 12]. Hsp90 and p23, the molecular
chaperones, are required for the assembly of active tel-
omerase holoenzyme by binding to the catalytic subunit
of telomerase [28]. Geldanamycin, another Hsp90 an-
tagonist, blocks assembly of active telomerase in cells.
Therefore, radicicol is also thought to affect telomerase
activity through interaction with Hsp90.
Thus, identification of a new chemical class of telome-
rase inhibitors demonstrated the utility of the yeast-based assay used in this study for discovery of small-
molecule inhibitors of human telomerase.
Chrolactomycin Is a Lead Compound
as a Novel Telomerase Inhibitor
Chrolactomycin was a novel microbial metabolite iso-
lated in our laboratories, but its biological activity had
not been investigated sufficiently. In addition to the tel-
omerase inhibition detected with an in vitro enzyme as-
say, consistent results of analyses with several human
cancer cell lines confirm that chrolactomycin exhibits
telomerase inhibitory activity at the cellular level.
Long-term culture of ACHN cells with chrolactomycin
revealed population-doubling-dependent antiprolifera-
tive activity accompanied by telomere shortening. At
late passage, chrolactomycin-treated ACHN cells ex-
hibited distinctive features associated with cellular se-
nescence and an increase in the G2/M and aneuploid
fractions. Similar results have been previously reported
in cases of inhibition of telomerase by epigallocatechin
gallate [22], BIBR1532/BIBR1591 [23], TNQX [24], and
hTERT-shRNA [29]. These results suggest that chrolac-
tomycin meets the criteria for a telomerase inhibitor and
may be useful for the development of new antitumor
agents acting on human telomerase.
Structural studies of chrolactomycin showed that the
exomethylene group is the structural feature responsible
for inhibition of telomerase. The exomethylene group
can react with a biological nucleophile, especially the
sulfhydryl group of a cysteine residue, by a Michael-
type reaction. Among known telomerase inhibitors, the
isothiazolone moiety of TMPI, a telomerase inhibitor,
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188Figure 5. Cell Cycle Distribution and Senes-
cence-Associated b-Galactosidase Staining
in ACHN Cells Treated with Chrolactomycin
(A) Cells were harvested after 46 days of
treatment with 1 or 2 mM chrolactomycin.
Cell fixation, RNA hydrolysis, and DNA stain-
ing with propidium iodide were performed.
(B) Cells were harvested after 50 days of
treatment with 2 mM chrolactomycin. Cell fix-
ation and senescence-associated b-galacto-
sidase staining with X-Gal were performed
(original magnification, 3200).was reported to interact potentially with the sulfhydryl
group of one or more cysteine residues at or near the ac-
tive site of telomerase [30]. The CP motif in the N-terminal
region of TERT included an evolutionarily conserved cys-
teine residue that has been demonstrated to be required
for binding of TR [31, 32]. Therefore, chrolactomycin
might covalently bind to the cysteine residue in the CP
motif of TERT through a Michael addition reaction with
the exomethylene group, resulting in inhibition of telo-
merase activity. In addition, as an example of an inhibitor
with a similar mode of action, PD 168393, a Michael ac-
ceptor-containing inhibitor, was designed to covalently
modify an active site cysteine of ErbB family tyrosine ki-
nase [33]. The irreversibility of PD 168393 has been dem-
onstrated to confer a significant therapeutic advantage
over equally potent reversible analogs in terms of in
vivo tumor suppression. Considering these unique fea-
tures of the mode of action of chrolactomycin, we are
currently proceeding to structure-activity relationship
studies to optimize its efficacy and evaluation of the an-
titumor activity of chrolactomycin in in vivo mouse
models.Significance
Cell-based screening havebeen shown tohave several
advantages, such as an increased efficiency in selec-
tion of cell-permeable small molecules and an ability
to identify the small molecules with several modes of
action. Since the telomere-shortened yeast strain rap-
idly entered cell senescence and exhibited a growth-
defective phenotype in the absence of active telome-
rase, we therefore attempted to develop a new assay
system for drug candidates acting on telomeres and
telomerase by applying yeast genetics. Consistent
with this expectation, screening with this yeast-based
assay allowed us to identify three structurally diversi-
fied natural products, chrolactomycin, UCS1025A, and
radicicol. Chrolactomycin and UCS1025A were novel
microbial metabolites produced by Streptomyces sp.
andAcremonium sp. andwere isolated in our laborato-
ries, but their biological activities had not been inves-
tigated sufficiently. Inhibitory studies against human
telomerase from human cancer cells in cell-free and
cellular systems indicated that active compounds
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rase inhibitors: direct inhibitors (chrolactomycin and
UCS1025A) and an indirect inhibitor via inhibiting
Hsp90 function (radicicol). Thus, identification of
new telomerase inhibitors demonstrated the utility of
the yeast-based assay used in this study for discovery
of small-molecule inhibitors of human telomerase.
Furthermore, long-term culture of cancer cells with
chrolactomycin revealed population-doubling-depen-
dent antiproliferative activity accompanied by telo-
mere shortening and expression of a senescence-as-
sociated phenotype. Therefore, chrolactomycin,
which meets the criteria for a telomerase inhibitor,
might be a useful lead for the development of new an-
titumor agents acting on human telomerase.
Experimental Procedures
Chemicals
Chrolactomycin, UCS1025A, radicicol, and wortmannin were pro-
duced by fermentation and were purified in our laboratories. Nysta-
tin, 5-fluorouracil, and ketoconazole were purchased from Sigma.
Yeast Strains and Plasmids
Yeast strains were maintained by using standard media and growth
conditions. Yeast strains used in this study were derived from Sac-
charomyces cerevisiae NBW6 (MATa pho3-1 leu2 ura3 his3 trp1
ade2 can1). The EST1 gene was cloned by PCR by using yeast geno-
mic DNA as a template. KY19504 (MATa pho3-1 leu2 ura3 his3 trp1
ade2 can1 DEST1::URA3) was produced by one-step gene replace-
ment ofEST1. EST1 disruption was confirmed by Southern blot anal-
ysis. The plasmid pHK209 expressing the EST1 gene controlled by
the GAL1 promoter is a YCp-based plasmid containing the LUE2
selectable marker. KY19614 (MATa pho3-1 leu2 ura3 his3 trp1
ade2 can1 DEST1::URA3 [ LEU2 GAL1-EST1]) was constructed by
transformation of KY19504 with pHK209.
Screening System for Telomerase Inhibitors in Yeast
The level of expression of EST1 could be controlled by the carbon
source of media for S. cerevisiae KY19614. After this yeast was sub-
cultured 7–9 times on agar medium containing glucose as a carbon
source, it entered cell senescence and exhibited a growth-defective
phenotype accompanied by telomere shortening. Therefore, cells
harvested just before they entered cell senescence were used as
a test strain, and they were named the telomere-shortened yeast
strain. Two kinds of yeast cells with different telomere lengths
were used for assay. One of the test strains was a telomere-short-
ened yeast strain, and another was a telomere-elongated yeast
strain. Both were grown in synthetic medium containing 20 g/l galac-
tose, 2 g/l sucrose, 7 g/l yeast nitrogen based without amino acid, 50
mg/l histidine, 50 mg/l tryptophan, and 50 mg/l adenine.
Cell Culture
Human renal adenocarcinoma ACHN cells were purchased from
American Type Culture Collection. Cells were maintained at 37ºC
in a humidified atmosphere containing 5% CO2. Cells were culture
in MEM supplemented with 10% FBS, 2 mM L-glutamine, and 0.1
mM nonessential amino acids.
Measurement of Telomerase Activity
Telomerase activity was measured by a TRAP assay with the TRA-
PEZE XL telomerase detection kit (Intergen), which is a quantitative
fluorescent-labeled PCR system for the estimation of relative telo-
merase activity with the use of a PCR internal control. To prepare
cell extracts for telomerase assays, human epidermoid carcinoma
A431 cells were lysed in buffer containing 10 mM Tris-HCl (pH 7.5),
1 mM MgCl2, 1 mM EGTA, 0.1 mM benzamide, 0.5% 3-([3-cholami-
dopropyl]-dimethyl-ammonio)-1-propane sulfonate (CHAPS), and
10% glycerol. To evaluate the inhibitory activity of a test compound
under appropriate conditions, a titration experiment was performed
to determine an optimal amount of cell extract. Test compoundswere incubated with the extracts for 30 min at 30ºC. The intensities
of the PCR products were measured by using an ARVOsx 1420
multilabel counter (Wallac) to detect the levels of fluorescein and
sulphorhodamine with the appropriate excitation and emission fil-
ters. The levels of telomerase activity were quantified by the ratio
of the fluorescein intensity of the entire TRAP ladder to the sulpho-
rhodamine intensity of the internal control after the correction of
each fluorescent intensity for the negative control and the back-
ground.
Cell-Based Telomerase Assay
The cells were treated with different dilutions of test compounds for
7 days at 37ºC in a humidified atmosphere with 5% CO2. After
washing with PBS, cell lysate was prepared with lysis buffer (10
mM Tris-HCl [pH 7.5], 1 mM MgCl2, 1 mM EGTA, 0.1 mM benzamide,
5 mM b-mercaptoethanol, 0.5% CHAPS, and 10% glycerol). Extracts
with equivalent protein concentration were prepared and subjected
to TRAP analysis by using the TRAPEZE telomerase detection kit
(Intergen) for measurement of telomerase activity. After extension
of the substrate by telomerase, the products were amplified by
PCR, resolved in 12.5% polyacrylamide gels, and revealed by stain-
ing with SYBR Green I (Molecular Probes) and scanning with a Fluo-
rImager SI (Molecular Dynamics). Two distinct areas were evaluated
separately: the telomerase activity-related ladder bands and the 36
bp internal control band. The signals of the telomerase ladders of the
lanes were normalized to the intensities of the internal controls.
Long-Term Exposure Studies
Cells were grown in six-well plates at 1.1 3 105 cells/well. After pre-
incubation for 4–5 hr, cells were exposed to a nonacute cytotoxic
concentration of test compounds or an equivalent concentration
of DMSO (vehicle control) every 24 hr. Every 3–4 days, the cells in
control and drug-treated wells were trypsinized, counted, and re-
seeded. The remaining cells were collected and used for measure-
ments of telomerase activity, telomere length, and cell cycle distri-
bution.
Cell Cycle Analysis
Cells were harvested by trypsin-EDTA treatment, fixed with 70%
ice-cold ethanol, and stored at 4ºC. For flow cytometric analysis,
the RNA was hydrolyzed with 250 mg/ml RNase A (type 1-A; Sigma)
at 37ºC for 30 min, and the cells were stained with propidium iodide
(Sigma) for 20 min. The DNA content of cells was analyzed with an
EPICS ELITE flow cytometer (Coulter Electronics).
Human TRF Length Analysis
Human genomic DNA was extracted with DNAzol (GIBCO-BRL). A
total of 5 mg DNA was digested with HinfI/RsaI and separated by
0.5% agarose gel electrophoresis. The gels were dried with a gel
dryer, denatured (0.5 M NaOH, 1.5 M NaCl) at room temperature
for 30 min, and neutralized (0.5 M Tris-HCl [pH 7.0], 1.5 M NaCl) for
15 min. Gels were prehybridized in hybridization buffer (0.5 M
Na2HPO4, 1 mM EDTA [pH 7.2], 1% BSA, and 7% SDS) at 37ºC for
1 hr. Gels were then hybridized with the end-labeled, single-
stranded telomeric oligonucleotide, (TTAGGG)3, probe prepared
with a DNA 50 end labeling kit (MEGALABEL, TaKaRa) at 37ºC over-
night, and they were washed with 0.53 SSC for 10 min twice and
dried with a gel dryer for 30 min. To determine TRF length,
a BAS2000 (Fuji Photo Film) was used to quantitate the strength of
the radioactive signal in each lane.
Senescence-Associated b-Galactosidase Staining
Cells were washed in PBS, fixed with 2% formaldehyde and 0.2% gl
utaraldehyde in PBS at room temperature, washed in PBS, and incu-
bated for 16 hr in staining solution (1 mg/ml 5-bromo-4-chloro-3-
indolyl-b-D-galactoside [X-Gal], 40 mM citric acid/sodium phosphate
(pH 6.0), 5 mM potassium ferrocyanide, 5 mM potassium ferricya-
nide, 150 mM NaCl, and 2 mM MgCl2).
Supplemental Data
Supplemental Data including information on telomere shortening by
radicicol in yeast are available at http://www.chembiol.com/cgi/
content/full/13/2/183/DC1/.
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